A comparison of verapamil and nifedipine on quality of life.
A comparison of verapamil and nifedipine on quality of life.
复制标题
维拉帕米和硝苯地平对生活质量的比较。
DOI：
10.1111/j.1365-2125.1990.tb03785.x
复制
发表时间：
1990
影响因子：
3.4
通讯作者：
C. Bulpitt
中科院分区：
文献类型：
--
作者：
A. Palmer;A. Fletcher;G. Hamilton;S. Muriss;C. Bulpitt
1.在一项为期4个月的随机双盲试验中，通过自填问卷评估生活质量（症状、心理健康和活动）方面，比较滴定剂量的维拉帕米缓释剂（n = 41）与硝苯地平缓释剂（n = 40）。要求未接受治疗的舒张压为95-115 mm Hg才能入选试验。2.两组的平均年龄为55岁。两种药物之间的显着差异，发现在平均报告的症状与硝苯地平增加（P <0.01）。硝苯地平组踝关节肿胀和潮红（P <0.05）增加，维拉帕米组踝关节肿胀（P <0.05）增加。精神病发病率的措施往往改善维拉帕米和恶化硝苯地平。只有认知功能的变化是显着的药物之间，更糟糕的硝苯地平（P = 0.05）。3.在舒张压下降方面，两组之间没有差异（硝苯地平组平均18 mm Hg，维拉帕米组平均17 mm Hg）。硝苯地平组收缩压下降幅度（23 mm Hg）明显大于维拉帕米组（13 mm Hg）（P <0.01）。4.这两种药物对生活质量的影响不同。维拉帕米对症状主诉和心理健康的改善可能是由于纳入试验，尽管我们不能排除药物作用的可能性。相反，硝苯地平引起的症状增加和自我评估的认知障碍被认为是药物的副作用。
1. Aspects of quality of life (symptoms, psychological well-being and activity) were evaluated by self-administered questionnaires in a 4 month randomised double-blind trial of titrated doses of verapamil slow release (n = 41) compared with nifedipine retard (n = 40). An untreated diastolic blood pressure of 95-115 mm Hg was required for inclusion in the trial. 2. The mean age in both groups was 55 years. A significant difference between the two drugs was found in the average reporting of symptoms with an increase on nifedipine (P less than 0.01). The reporting of swollen ankles and flushing (P less than 0.05) increased on nifedipine, and nocturia (P less than 0.05) increased on verapamil. Measures of psychiatric morbidity tended to improve on verapamil and deteriorate on nifedipine. Only the change in cognitive function was significant between the drugs, being worse on nifedipine (P = 0.05). 3. There was no difference between the two groups in the fall in diastolic blood pressure (average 18 mm Hg on nifedipine and 17 mm Hg on verapamil). There was a significantly greater fall in systolic blood pressure on nifedipine (23 mm Hg) compared with verapamil (13 mm Hg) (P less than 0.01). 4. The two drugs differed in their effects on measures of quality of life. The improvements in symptomatic complaints and psychological well-being on verapamil may have been due to inclusion in a trial, although we cannot exclude the possibility of a drug effect. Conversely the increase in symptoms and self-assessed cognitive impairment on nifedipine were considered to be side-effects of the drug.